To reduce a universe of potential investments to a few to study and perhaps even buy, ask a few threshold questions. For example, to pass the sentry, a business must answer, "yes" to: "Are you run by experienced leaders who allocate cash to increase shareholder value?" (Last week's question was whether the financials clearly convey the business model and health, allowing the investor to evaluate risk.)
Today, the first half: Who on earth are "experienced people?" Answers to this question line bookshelves, fill terabytes and checklists pages long. Our own How to Evaluate Management special should be every investor's bedside reading. But here are some quick tools to get you started and narrow your candidates for more detailed work.
Experienced people
I simply want managers who are experienced in the task at hand. That means either that they have a track record in the industry or in turnarounds, or both. I make exceptions for a few stars that could probably lead any company, any time. But while I admire visionaries with more dreams than experience, I like to see experienced senior management with complementary skills.
This is easy to ascertain. Simply use our Quotes & Data service or www.sec.gov to find the annual report Form 10-K or Proxy Statement Form DEF-14 to read up on management's background (available through the Fool or www.sec.gov). Make your life easier by using CTRL+F to search through your online documents by keyword.
Almost all websites for publicly traded companies contain bios of top management. It's not a good sign if they don't or if details are sketchy.
All-stars
You don't necessarily need experience in a particular industry if you are just plain stellar. When General Electric
But apart from that limited universe, you want industry experience, turnaround expertise, or both.
Everybody else
Consider Oxford Health Plan's
Ailing drugmaker Schering-Plough
Bankrate
Bankrate kept losing money and its shares dipped to $0.19 after Christmas 2000 and were delisted from the Nasdaq a month later. DeMarse and her team started squeezing free cash flow in 2001. The stock recovered a little, but investors really didn't catch on until the second half 2002. As free cash flow accelerated, the stock began to catch fire, rejoined the Nasdaq SmallCap Market early this year, and ascended to the National Market in August. It closed yesterday at $13.51, providing a nice 7,011% gain from Dec. 26, 2000. Quite a Christmas present -- a gift that kept on giving.
The task at hand
When another ailing drugmaker, Elan Pharmaceuticals
And Martin has made great progress, leading investors to raise the stock from its $1.17 close on Oct. 9, 2002 to yesterday's $5.33. Jeff Hwang snapshots the company in Elan's Bitter Pill.
Vision plus experience
Vision is necessary for a business that wants to upend the established order, but it's best to have some experience on the team. Young, brash and brilliant founder and CEO Doug Lebda had the good sense to hire skilled senior people at online lending exchange LendingTree, which he eventually sold for a 48% premium to InterActive Corp.
eBay
Obvious exceptions
Applying these simple tests makes it easy to spot pretenders to the executive thrones. Those who examined Al Dunlap's experience prior to Sunbeam steered clear, and investors familiar with Gaston Bastiens' sub-par tenure at Quarterdeck avoided the Lernout & Hauspie debacle.
Investors considering Elan Pharmaceuticals before its blow-up might have noticed that top execs had been partners at accounting firm KPMG. No wonder they cottoned to special purpose entities -- the same that imploded Enron -- to carry off-balance sheet debt and fund all sorts of development deals. They were better at juggling balance sheets than developing and selling drugs.
A stitch in time...
With online access to so much information today, it's easy to get to know managements' backgrounds and gauge their chances of success in making you money. You can spare a half hour to apply the easy test: Does management stand in the star category ready to handle all, or is it at least experienced in the industry, turnarounds, or both?
Next week, the second half of the management test: Which execs do a great job allocating cash to increase shareholder value, how do they do it, and how can you tell? Once again, I'll name names.
Have a most Foolish week, and thanks for reading!
Senior Analyst Tom Jacobs owns shares of Oxford Health. To see his stock holdings, view his profile , and check out The Motley Fool's disclosure policy.
